ANXA2	annexin A2
ASCO	American Society of Clinical Oncology
ASCT	autologous stem cell transplantation
BMSC	bone marrow stromal cell
CCL3	chemokine ligand 3
CrCl	creatinine clearance
DKK-1	Dickkopf-related protein 1
HSPG	heparan sulfate proteoglycan
IMWG	International Myeloma Working Group
ISS	international staging system
IV	intravenous
MM	multiple myeloma
NCCN	National Comprehensive Cancer Network
NDMM	newly diagnosed multiple myeloma
ONJ	osteonecrosis of the jaw
OPG	osteoprotegerin
OS	overall survival
PI	Proteosome Inhibitor
PFS	progression-free survival
RVD	lenalidomide (Revlimid), bortezomib (Velcade), dexamethasone
S1	syndecan-1
Sema4D	Semaphorin 4D
SDF-1α	stromal cell-derived factor-1α
sFRPs	soluble frizzled-related proteins
SRE	skeletal-related event
TNF-α	tumor necrosis factor-α
TGF-β	transforming growth factor-beta
VCAM-1	vascular cell adhesion molecule-1
VCD	bortezomib (Velcade), cyclophosphamide, dexamethasone
VGPR	very good partial response
VLA-4	very late antigen-4
VTD	bortezomib (Velcade), thalidomide, dexamethasone
VD	bortezomib (Velcade), dexamethasone